Program
GS 101
Also written as “GS101 injection” and “aganirsen”.
Its studies are mostly in Dermatitis, Atopic · Glaucoma, Neovascular, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu Genscend Biopharmaceutical | 21 open or running | phase 3since Jan 26, 2026 | Jan 26, 2026 | Apr 2027phase 3 · NCT07386743 |
| Gene Signal SAS | 10 open or running | phase 3since Oct 15, 2016 | Oct 15, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2016First study: phase 3 study in Glaucoma, NeovascularNew to Gene Signal SASGene Signal SAS · NCT02947867 · 333 enrolled
- Jan 26, 2026Jiangsu Genscend Biopharmaceutical's first study: phase 3 study in Dermatitis, AtopicNew to Jiangsu Genscend BiopharmaceuticalJiangsu Genscend Biopharmaceutical · NCT07386743 · 572 planned · China
- Feb 9, 2026Phase 1 study in Dermatitis, AtopicJiangsu Genscend Biopharmaceutical · NCT07411755 · 294 enrolled · China
Ahead
- Apr 2027Primary completion: phase 3 study in Dermatitis, AtopicJiangsu Genscend Biopharmaceutical · NCT07386743
TargetBeta
“A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07411755Dermatitis, Atopic · China | 1 | Completed | Jiangsu Genscend Biopharmaceutical | Aug 8, 2026 | 294 |
| NCT07386743Dermatitis, Atopic · China | 3 | Recruiting | Jiangsu Genscend Biopharmaceutical | Apr 2027 | 572 |
| NCT02947867Glaucoma, Neovascular | 3 | UNKNOWN | Gene Signal SAS | Jun 2019 | 333 |
How it is read
Names in the registry
- “GS101 injection”, 2 entries
- “aganirsen”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Glaucoma, Neovascular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.